test
test
test
test
test
test
test
test
test
test
Key nasal examination findings in a patient with Allergic Rhinitis
Key nasal examination findings in a patient with Allergic Rhinitis
Key nasal examination findings in a patient with Allergic Rhinitis
Impact of exposure of Allergic Rhinitis patient to trigger factors
Impact of exposure of Allergic Rhinitis patient to trigger factors
Impact of exposure of Allergic Rhinitis patient to trigger factors
Considerations for reaching the diagnosis of Allergic Rhinitis
Considerations for reaching the diagnosis of Allergic Rhinitis
Considerations for reaching the diagnosis of Allergic Rhinitis
The impact of Allergic Rhinitis on the quality of life of the patient
The impact of Allergic Rhinitis on the quality of life of the patient
The impact of Allergic Rhinitis on the quality of life of the patient
According to a new study, oscillatory positive expiratory pressure (OPEP) devices were found to improve the symptoms and quality of life in COPD patients. This study was published in the journal, Thorax.
A randomized controlled trial enrolled 122 stable patients with COPD, who reported sputum production every day or on most days. This trial compared 61 participants for a period 3 months of using an OPEP device (test group) against 61 participants getting usual care (control group).
The use of OPEP devices was associated with an improvement in the cough-related quality of life in the test group when compared to the control group measured using the Leicester Cough Questionnaire (LCQ). The Functional Assessment of Chronic Illness Therapy (FACIT score) and generic quality of life demonstrated improved symptoms, an improvement in cough frequency was also seen in the OPEP group compared to the control group.
According to a new study, oscillatory positive expiratory pressure (OPEP) devices were found to improve the symptoms and quality of life in COPD patients. This study was published in the journal, Thorax.
A randomized controlled trial enrolled 122 stable patients with COPD, who reported sputum production every day or on most days. This trial compared 61 participants for a period 3 months of using an OPEP device (test group) against 61 participants getting usual care (control group).
The use of OPEP devices was associated with an improvement in the cough-related quality of life in the test group when compared to the control group measured using the Leicester Cough Questionnaire (LCQ). The Functional Assessment of Chronic Illness Therapy (FACIT score) and generic quality of life demonstrated improved symptoms, an improvement in cough frequency was also seen in the OPEP group compared to the control group.
According to a new study, oscillatory positive expiratory pressure (OPEP) devices were found to improve the symptoms and quality of life in COPD patients. This study was published in the journal, Thorax.
A randomized controlled trial enrolled 122 stable patients with COPD, who reported sputum production every day or on most days. This trial compared 61 participants for a period 3 months of using an OPEP device (test group) against 61 participants getting usual care (control group).
The use of OPEP devices was associated with an improvement in the cough-related quality of life in the test group when compared to the control group measured using the Leicester Cough Questionnaire (LCQ). The Functional Assessment of Chronic Illness Therapy (FACIT score) and generic quality of life demonstrated improved symptoms, an improvement in cough frequency was also seen in the OPEP group compared to the control group.
The findings of a recent study suggest that camrelizumab when combined with first-line chemotherapy, shows significant effect on serum SCC (Squamous Cell Carcinoma - Antigen), VEGF (vascular endothelial growth factor) levels and adverse reactions in people with advanced lung squamous cell carcinoma (SCC).
The results of the study were published in the journal, Computational intelligence and neuroscience. The study included 60 people with advanced squamous cell carcinoma of the lung, hospitalized from January 2018 to October 2019. These participants were randomized into two groups of 30 each: the observation group received camrelizumab (SHR-1210) while gemcitabine plus cisplatin (GP) chemotherapy was given to the control group.
The effective efficiency of the clinical treatment in the observation group reached 56.67%, and that in the control group reached 36.67%. The observed group had higher periodic survival and progression free survival (PFS) of patients than the control group.
Thus, the results of the study indicate that camrelizumab (SHR-1210) when combined with chemotherapy can have significant effects on serum SCC, VEGF levels and adverse reactions in people with advanced lung squamous cell carcinoma.
The findings of a recent study suggest that camrelizumab when combined with first-line chemotherapy, shows significant effect on serum SCC (Squamous Cell Carcinoma - Antigen), VEGF (vascular endothelial growth factor) levels and adverse reactions in people with advanced lung squamous cell carcinoma (SCC).
The results of the study were published in the journal, Computational intelligence and neuroscience. The study included 60 people with advanced squamous cell carcinoma of the lung, hospitalized from January 2018 to October 2019. These participants were randomized into two groups of 30 each: the observation group received camrelizumab (SHR-1210) while gemcitabine plus cisplatin (GP) chemotherapy was given to the control group.
The effective efficiency of the clinical treatment in the observation group reached 56.67%, and that in the control group reached 36.67%. The observed group had higher periodic survival and progression free survival (PFS) of patients than the control group.
Thus, the results of the study indicate that camrelizumab (SHR-1210) when combined with chemotherapy can have significant effects on serum SCC, VEGF levels and adverse reactions in people with advanced lung squamous cell carcinoma.
The findings of a recent study suggest that camrelizumab when combined with first-line chemotherapy, shows significant effect on serum SCC (Squamous Cell Carcinoma - Antigen), VEGF (vascular endothelial growth factor) levels and adverse reactions in people with advanced lung squamous cell carcinoma (SCC).
The results of the study were published in the journal, Computational intelligence and neuroscience. The study included 60 people with advanced squamous cell carcinoma of the lung, hospitalized from January 2018 to October 2019. These participants were randomized into two groups of 30 each: the observation group received camrelizumab (SHR-1210) while gemcitabine plus cisplatin (GP) chemotherapy was given to the control group.
The effective efficiency of the clinical treatment in the observation group reached 56.67%, and that in the control group reached 36.67%. The observed group had higher periodic survival and progression free survival (PFS) of patients than the control group.
Thus, the results of the study indicate that camrelizumab (SHR-1210) when combined with chemotherapy can have significant effects on serum SCC, VEGF levels and adverse reactions in people with advanced lung squamous cell carcinoma.
A latest study has reported that starting Non-Invasive respiratory support (NRS) as Continuous Positive Airway Pressure (CPAP) and/or Non-Invasive Ventilation (NIV) in moderate stage (100 > PaO2/FiO2 ≤ 200) in patients with SARS-CoV-2-related acute respiratory distress syndrome (ARDS) is beneficial. This study was published in the journal, Respiratory Research.
This randomized, prospective pilot study included patients who developed moderate SARS-CoV-2-related ARDS during hospitalization. Participants were randomized into intervention groups based on ADRS severity assessed by PaO2/FiO2 (P/F). Group A received CPAP/NIV when P/F was ≤ 200, group B received CPAP/NIV when P/F ≤ 150 and group C received CPAP/NIV when P/F ≤ 100. The outcomes evaluated were in-hospital mortality, oro-tracheal intubation (OTI) and days of hospitalization.
Participants who underwent CPAP/NIV in a moderate stage (P/F 101-200) had a significant reduction in-hospital mortality rate and hospitalization length than those in the severe stage (P/F ≤ 100).
The results of the study indicate that recommending CPAP/NIV in patients with SARS-CoV-2-related ARDS is effective in moderate stage (100 > P/F ≤ 200) compared to the severe stage (P/F ≤ 100).
A latest study has reported that starting Non-Invasive respiratory support (NRS) as Continuous Positive Airway Pressure (CPAP) and/or Non-Invasive Ventilation (NIV) in moderate stage (100 > PaO2/FiO2 ≤ 200) in patients with SARS-CoV-2-related acute respiratory distress syndrome (ARDS) is beneficial. This study was published in the journal, Respiratory Research.
This randomized, prospective pilot study included patients who developed moderate SARS-CoV-2-related ARDS during hospitalization. Participants were randomized into intervention groups based on ADRS severity assessed by PaO2/FiO2 (P/F). Group A received CPAP/NIV when P/F was ≤ 200, group B received CPAP/NIV when P/F ≤ 150 and group C received CPAP/NIV when P/F ≤ 100. The outcomes evaluated were in-hospital mortality, oro-tracheal intubation (OTI) and days of hospitalization.
Participants who underwent CPAP/NIV in a moderate stage (P/F 101-200) had a significant reduction in-hospital mortality rate and hospitalization length than those in the severe stage (P/F ≤ 100).
The results of the study indicate that recommending CPAP/NIV in patients with SARS-CoV-2-related ARDS is effective in moderate stage (100 > P/F ≤ 200) compared to the severe stage (P/F ≤ 100).
A latest study has reported that starting Non-Invasive respiratory support (NRS) as Continuous Positive Airway Pressure (CPAP) and/or Non-Invasive Ventilation (NIV) in moderate stage (100 > PaO2/FiO2 ≤ 200) in patients with SARS-CoV-2-related acute respiratory distress syndrome (ARDS) is beneficial. This study was published in the journal, Respiratory Research.
This randomized, prospective pilot study included patients who developed moderate SARS-CoV-2-related ARDS during hospitalization. Participants were randomized into intervention groups based on ADRS severity assessed by PaO2/FiO2 (P/F). Group A received CPAP/NIV when P/F was ≤ 200, group B received CPAP/NIV when P/F ≤ 150 and group C received CPAP/NIV when P/F ≤ 100. The outcomes evaluated were in-hospital mortality, oro-tracheal intubation (OTI) and days of hospitalization.
Participants who underwent CPAP/NIV in a moderate stage (P/F 101-200) had a significant reduction in-hospital mortality rate and hospitalization length than those in the severe stage (P/F ≤ 100).
The results of the study indicate that recommending CPAP/NIV in patients with SARS-CoV-2-related ARDS is effective in moderate stage (100 > P/F ≤ 200) compared to the severe stage (P/F ≤ 100).
A recent study found that exercise intensity modifies the acute inflammatory response to exercise in adults with asthma. The findings of the study were published in Annals of the American Thoracic Society.
The trial aimed to conduct a comparison of acute changes in airway and systemic inflammation after a period of moderate or vigorous exercise in physically inactive adults with asthma and to establish whether these effects differ according to asthma phenotype in 56 participants. The participants were randomized to either control (no intervention), 45 mins of moderate exercise or 30 mins of vigorous exercise. At baseline and 4 hours after intervention, induced sputum and blood samples were collected.
At the end of trial, it was found that moderate exercise induced a significant reduction in sputum eosinophil count and sputum percentage eosinophils relative to control. Comparatively, vigorous exercise had no effect on airway inflammation. It was also found that moderate exercise had the greatest anti-inflammatory effects in participants with eosinophilic asthma. As a result, it was concluded that the intensity of exercise modifies the acute inflammatory response to exercise in adults with asthma.
A recent study found that exercise intensity modifies the acute inflammatory response to exercise in adults with asthma. The findings of the study were published in Annals of the American Thoracic Society.
The trial aimed to conduct a comparison of acute changes in airway and systemic inflammation after a period of moderate or vigorous exercise in physically inactive adults with asthma and to establish whether these effects differ according to asthma phenotype in 56 participants. The participants were randomized to either control (no intervention), 45 mins of moderate exercise or 30 mins of vigorous exercise. At baseline and 4 hours after intervention, induced sputum and blood samples were collected.
At the end of trial, it was found that moderate exercise induced a significant reduction in sputum eosinophil count and sputum percentage eosinophils relative to control. Comparatively, vigorous exercise had no effect on airway inflammation. It was also found that moderate exercise had the greatest anti-inflammatory effects in participants with eosinophilic asthma. As a result, it was concluded that the intensity of exercise modifies the acute inflammatory response to exercise in adults with asthma.
A recent study found that exercise intensity modifies the acute inflammatory response to exercise in adults with asthma. The findings of the study were published in Annals of the American Thoracic Society.
The trial aimed to conduct a comparison of acute changes in airway and systemic inflammation after a period of moderate or vigorous exercise in physically inactive adults with asthma and to establish whether these effects differ according to asthma phenotype in 56 participants. The participants were randomized to either control (no intervention), 45 mins of moderate exercise or 30 mins of vigorous exercise. At baseline and 4 hours after intervention, induced sputum and blood samples were collected.
At the end of trial, it was found that moderate exercise induced a significant reduction in sputum eosinophil count and sputum percentage eosinophils relative to control. Comparatively, vigorous exercise had no effect on airway inflammation. It was also found that moderate exercise had the greatest anti-inflammatory effects in participants with eosinophilic asthma. As a result, it was concluded that the intensity of exercise modifies the acute inflammatory response to exercise in adults with asthma.
Join our sessions by completing the form below.
